ABSTRACT GUIDELINES

Abstracts must be submitted electronically via the conference website. No faxed or mailed abstracts will be accepted. There are no exceptions to the deadline as the review period ensues immediately after the submission site closes.


Official Language
All presentations at APASL Annual Meeting 2018 will be in English.

Submission Categories
Authors must select a submissions category when submitting their abstract. Please find the below Full List Of Abstract Submission Categories:

Acute Liver Failure and Artificial Liver Support-Clinical
• CA-01 Acute Liver Failure and Artificial Liver Support-Clinical

Acute Liver Failure and Artificial Liver Support- Basic
BA-01 Acute Liver Failure and Artificial Liver Support-Basic Science

Alcoholic Liver Disease-Clinical
• CAL-01 Alcoholic Liver Disease: Clinical and Therapeutic

Alcoholic Liver Disease-Basic
• BAL-01 Alcoholic Liver Disease: Experimental

Hepatitis B and D-Clinical
• CB-01 Diagnostics, Epidemiology, Prevention, Natural History
• CB-02 Therapeutics: New and Approved

Hepatitis B and D-Basic
• BB-01 Virology, Pathogenesis, and Immunology

Biliary and pancreatic Neoplasia other than Liver cancer-Clinical
• CBN-01 Diagnostics and Liver Imaging of biliary and pancreatic neoplasia
• CBN-02 Prognosis : biliary and pancreatic neoplasia
• CBN-03 Surgery and Loco-Regional Therapy for biliary and pancreatic neoplasia
• CBN-04 Targetted and systemic therapies for biliary and pancreatic neoplasia

Biliary and pancreatic Neoplasia other than Liver cancer-Basic
• BBN-01 Experimental carcinogenesis of biliary and pancreatic neoplasia

Hepatitis C-Clinical
• CC-01 Diagnostics, Epidemiology, Natural History
• CC-02 Therapeutics: Preclinical and Early Clinical Development
• CC-03 Therapeutics: New Agents (not approved, phase 2-3)
• CC-04 Therapeutics: Approved Agents

Hepatitis C-Basic
• BC-01 Virology, Pathogenesis, and Immunology

Cholestatic and Autoimmune Liver Diseases-Clinical
• CCA-01 PBC/PSC and Other Cholestatic Disease: Clinical and Therapeutics
• CCA-02 Autoimmune Liver Disease: Clinical and Therapeutics

Cholestatic and Autoimmune Liver Diseases-Basic
• BCA-01 Transport, Bilirubin, Cholesterol, Lipids and Bile Salts,   Cholangiocyte Biology and   Experimental Cholestasis
• BCA-02 Autoimmune Liver Disease:Experimental

Drug Induced Liver Injury-Clinical
• CD-01 Predictors of Drug Toxicity and Therapy

Drug Induced Liver Injury-Basic
• BD-01    Pathogenesis and Mechanisms
• BD-02    Drug Metabolism, and Toxicity

Hepatitis A and E-Clinical
• CE-01 Hepatitis A and E- Clinical and Therapeutic

Hepatitis A and E-Basic
• BE-01 Hepatitis A and Experimental

Liver Fibrogenesis and Non-Parenchymal Cell Biology-Clinical
• BF-01 Imaging and Noninvasive Markers of Liver Fibrosis 
• BF-02 Clinical and Translational Fibrosis Research and Therapy

Liver Fibrogenesis and Non-Parenchymal Cell Biology-Basic
• BF-01 Basic Fibrosis Research and Stellate Cell Biology

Genetic and Metabolic Disease-Clinical
• CG-01 Hemochromatosis, Wilson Disease, ∝-1 Antitrypsin Deficiency-Clinical
CG-02 Other genetic and metabolic disorders-Clinical

Genetic and Metabolic Disease-Basic
• BG-01 Hemochromatosis, Wilson Disease, ∝-1 Antitrypsin Deficiency-Experimental
BG-02 Other genetic and metabolic disorders-Experimental

Inflammation and Immunology-Basic
• BI-01 Animal Models
• BI-02 Innate Immunity
• BI-03 Adaptive Immunity
• BI-04 Mechanisms of Injury and others

Liver Cancer -Clinical
• CLC-01 Diagnostics and Liver Imaging of hepatocellular carcinoma
• CLC-02 Prognosis : Hepatocellular Carcinoma
• CLC-03 Liver transplantation, Surgery and Loco-Regional Therapy for Hepatocellular Carcinoma
• CLC-04 Targetted and systemic therapies for Hepatocellular Carcinoma

Liver Cancer -Basic
• BLC-01 Experimental Hepatocarcinogenesis

Liver Transplantation and Liver Surgery-Clinical
• CLTS-01 Donor and Allocation Issues; Living Donor and Split Liver Transplantation,
• CLTS-02 Immunosuppression, Outcomes, Complications of liver transplantation
• CLTS-03 Viral Hepatitis   and liver transplantation 
• CLTS-04 Hepatobiliary Surgery

Liver Transplantation and Liver Surgery-Basic
• BLTS-01 Cellular Immunobiology, Preservation and Cell Transplantation, Experimental

Molecular and Cellular  Biology and Stem Cell Therapy -Basic
• BM-01 Cell Structure; Function; Signal Transduction, Nuclear Receptors
• BM-02 Gene Expression and Gene Therapy
• BM-03 Stem Cell Biology- Basic Sciences
• BM-04 Stem cell therapy: Clinical

Non-alcoholic Fatty liver Disease-Clinical
• CNA-01 NAFLD: Clinical and Therapeutic

Non-alcoholic Fatty liver Disease-Basic
• BNA-01 NAFLD: Experimental

Portal Hypertension and Other Complications of Cirrhosis-Clinical
• CP-01 Ascites, Renal Dysfunction and Hepatorenal Syndrome
• CP-02 Varices and Bleeding
• CP-03 Encephalopathy and Infections and Other Complications
• C-P04 Acute on Chronic Liver Failure

Portal Hypertension and Other Complications of Cirrhosis including ACLF-Basic
• BP-01 Experimental\

Pediatric Hepatology-Clinical
• CPD-01 Biliary Atresia and Cholestasis
• CPD-02 Viral and Autoimmune Hepatitis
• CPD-03 Metabolic and Genetic Diseases
• CPD-04 Pediatric Liver Transplantation

Pediatric Hepatology-Basic
• BPD-01 Pediatric Liver Disease – Basic Science

Public Health Services Research
• CPH-01 Health Care Delivery/Access/Quality
• CPH-02 Health Economics and Cost-Effectiveness and Economics of Care
• CPH-03 Other public health issues

Miscellaneous-Clinical
• CM-01 Miscellaneous issues-Clinical

Miscellaneous-Basic
• BM-01: Miscellaneous issues-Experimental


Abstract Title

There is a limit of 300 characters, including spaces, for the title of an abstract.


Authors

Please list all authors with their affiliations (institution, city and country).


Authorship

Credit for authorship requires substantial contributions to the conception and design; or the acquisition, analysis, or interpretation of the data, final approval of the version to be published, and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.


Abstract Body
There is a limit of 3000 characters, including spaces, for the body of abstract submissions. Abstract titles, author names, author institutions, and information in tables and images do not count toward the 3000 character limit. Abstract text for original article should include 1) background/aims, 2) methods, 3) results and 4) conclusions. For case report, it should include introduction and case description. Do not include references and key words in the abstract.


Tables and Figures

A maximum of 2 images can be included per abstract. The maximum file size of each graph/image is 2M. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. Graphs and images may be uploaded in JPG, PNG and GIF format only. When including a table it is recommended to save the table as an image and then upload it in to the abstract.


Format
Use the abbreviation in parentheses after the full word the first time it appears.
To avoid character corruption, please use only Times New Roman font.
Font size should be 10.


Editing A Submitted Abstract
Authors may edit submitted abstracts until the submissions deadline. Abstract submitters should log into their registration account to make any edits.

Contact Us

Conference Secretariat


Conference Manager


  • Address:
    Summit - Alpcord Network
    1201, 12th Floor, New Delhi House, 27,
    Barakhamba Road, New Delhi - 110001
    Phone: +91 11 49104010
    Website: www.alpcord.com